Clinical trial
Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)
NCT03645486 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- July 1, 2027
- Completion date
- December 31, 2029
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic granulomatous disease